Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem-cell transplantation for primary immunodeficiencies.

Bella Bielorai1, Hana Golan, Gideon Rechavi

  • 1Department of Pediatric Hematology-Oncology and Bone Marrow Transplantation, Sheba Medical Center, Tel Hashomer, Israel.

The Israel Medical Association Journal : IMAJ
|August 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

The Lancet. Haematology·2026
Same author

PREDICTORS OF RESPONSE TO GROWTH HORMONE TREATMENT AND FINAL HEIGHT IN MEDULLOBLASTOMA SURVIVORS.

Hormone research in paediatrics·2026
Same author

The impact of pre-transplant extramedullary disease on the outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in children- on behalf of PDWP/EBMT.

Bone marrow transplantation·2026
Same author

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors.

Acta paediatrica (Oslo, Norway : 1992)·2026
Same author

The dilemma after chimeric antigen receptor T-cell therapy - to transplant or not?

Haematologica·2026
Same author

Targeting bladder cancer: Potent anti-cancer effects of cannabichromene and delta-9-tetrahydrocannabinol-rich <i>Cannabis sativa</i> strains.

Asian journal of urology·2025

Stem-cell transplantation offers a cure for primary immunodeficiency diseases, especially when performed in early infancy. Further research is needed to optimize transplantation protocols for better patient outcomes.

Area of Science:

  • Pediatric Hematology/Oncology
  • Immunology
  • Genetics

Background:

  • Primary immunodeficiency diseases (PIDs) are a group of genetic disorders affecting the immune system.
  • Currently, stem-cell transplantation (SCT) is the primary curative treatment for PIDs.
  • Advances in genetic understanding allow for early diagnosis and intervention.

Purpose of the Study:

  • To review the current state of stem-cell transplantation for primary immunodeficiency diseases.
  • To discuss the challenges and future directions in optimizing SCT protocols for pediatric patients.

Main Methods:

  • Review of current literature on SCT for PIDs.
  • Analysis of non-myeloablative conditioning protocols.
  • Discussion of factors influencing engraftment and patient outcomes.

Related Experiment Videos

Main Results:

  • Early SCT in infancy offers the highest chance of success.
  • Non-myeloablative protocols show promise for immune reconstitution with reduced toxicity, but experience is limited.
  • Tailoring conditioning regimens based on immune dysfunction and residual immunity is crucial.

Conclusions:

  • SCT remains the cornerstone for curing PIDs.
  • Further research is essential to determine optimal SCT approaches, particularly non-myeloablative protocols.
  • Personalized conditioning strategies are key to ensuring successful engraftment and minimizing morbidity in pediatric patients.